Overview

A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Status:
Completed

Trial end date:
2021-05-25

Target enrollment:

Participant gender:

Summary

This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Estrogens